Panagiota Tsagkli

Dr. Panagiota Tsagkli

National and Kapodistrian University of Athens, Athens, Attikí, Greece

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
PTPanagiota Tsagkli
Panagiota Tsagkli
MGMaria Geropeppa
Maria Geropeppa
IPIoanna Papadatou
Ioanna Papadatou
VSVana Spoulou
Vana Spoulou
The emergence of SARS-CoV-2 led to a global health crisis and the burden of the disease continues to persist. The rapid development and emergency authorization of various vaccines, including mRNA-based vaccines, played a pivotal role in mitigating severe illness and mortality. However, rapid viral mutations, leading to several variants of concern, challenged vaccine effectiveness, particularly concerning immune evasion. Research on immunity, both from natural infection and vaccination, revealed that while neutralizing antibodies provide protection against infection, their effect is short-lived. The primary defense against severe COVID-19 is derived from the cellular immune response. Hybrid immunity, developed from a combination of natural infection and vaccination, offers enhanced protection, with convalescent vaccinated individuals showing significantly higher levels of neutralizing antibodies. As SARS-CoV-2 continues to evolve, understanding the durability and breadth of hybrid immunity becomes crucial. This narrative review examines the latest data on humoral and cellular immunity from both natural infection and vaccination, discussing how hybrid immunity could inform and optimize future vaccination strategies in the ongoing battle against COVID-19 and in fear of a new pandemic.

18 November 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
TLTheano Lagousi
Theano Lagousi
DGDESPOINA GKENTZI
DESPOINA GKENTZI
MGMaria Geropeppa
Maria Geropeppa
PTPanagiota Tsagkli
Panagiota Tsagkli
VSVana Spoulou
Vana Spoulou
Pregnancy is characterized by immunological alterations in pregnant women that permit the growth of a semi-allogenic fetus, resulting in greater susceptibility of childbearing women to infections. Furthermore, due to the immaturity of the immune system of neonates, a protection gap is present in early life, leaving neonates and infants vulnerable to infectious diseases with increased morbidity and mortality. Maternal immunization against influenza, pertussis, and, in the context of the COVID-19 pandemic, SARS-CoV-2 has been implemented in several countries, with beneficial effects on both the mother and the offspring. The main protective mechanism of vaccination during pregnancy is transplacental transfer of maternal antibodies. However, recent evidence has implied that the fetal immune system may be influenced beyond passive immunity. This review sheds light on the current status of the routinely administered vaccinations during pregnancy, focusing on the impact of maternal immunization on the priming of the fetal immune system and suggesting future perspectives for the optimization of vaccination strategies.

18 March 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
DMDespoina N Maritsi
Despoina N Maritsi
IKIoannis Kopsidas
Ioannis Kopsidas
PTPanagiota Tsagkli
Panagiota Tsagkli
MTMaria N Tsolia
Maria N Tsolia
Despoina N Maritsi, Ioannis Kopsidas, Panagiota Tsagkli, Maria N Tsolia; Antibody status against measles and rubella in juvenile localized scleroderma patients